- Details
- Description
-
Packaging Size30T/bottle
-
Strength6mg
-
CompositonDeucravacitinib
-
TreatmentPsoriasis
-
FormTablet
-
BrandDUVACIDX
-
Quantity Unit6mg*30T/bottle
-
ManufacturerBIGBEAR Pharma,Laos PDR
What is deucravacitinib used for?
Deucravacitinib acts as a highly selective allosteric inhibitor of non-receptor tyrosine-protein kinase 2 (TYK2).It used to treat moderate to severe plaque psoriasis (a skin disease in which red, scaly patches form on some areas of the body) in adults 18 years of age or older whose psoriasis is too severe to be treated by topical medications alone.
Dosage for Deucravacitinib
The recommended dosage of Deucravacitinib is 6 mg orally once daily, with or without food.
The approval is based on results from the pivotal Phase 3 POETYK PSO-1 and POETYK PSO-2 clinical trials.The superior efficacy of Deucravacitinib compared to placebo and Otezla was demonstrated at both 16 and 24 weeks, and responses with Sotyktu persisted through 52 weeks.